Key result
Higher C-reactive protein levels were associated with mild cognitive impairment (OR 1.35; 95% CI 1.00-1.81; P=0.046) in patients with stage B heart failure.
Why the study?
The study investigated the role of systemic inflammation in reduced cognitive functioning among patients with early-stage heart failure while determining associations with other cardiovascular risk factors.
Does systemic inflammation correlate with cognitive decrements in patients with stage B heart failure?
Observational (n=270)
Does systemic inflammation correlate with cognitive decrements in patients with stage B heart failure?
Systemic inflammation, indicated by elevated CRP, is associated with worse cognitive function in patients with early-stage (stage B) heart failure.
Answers are grounded in this paper and cite their sources.
CRP elevation signals possible cognitive vulnerability in stage B HF; hypothesis-generating and should not yet change practice.
OBJECTIVE: This study aimed to investigate the role of systemic inflammation in reduced cognitive functioning in patients with early-stage heart failure (HF) while determining associations with other cardiovascular risk factors. METHODS: Patients with stage B HF (n = 270; mean [standard deviation] age = 66.1 [10.1] years) were examined cross-sectionally for relationships among cardiovascular disease (CVD) and psychological risk factors, C-reactive protein (CRP), and Montreal Cognitive Assessment (MoCA) scores. A subsample (n = 83) at high risk for stage C HF (B-type natriuretic peptide levels ≥65 pg/ml) were followed up for 12 months for relationships between CRP levels and cognitive function. RESULTS: Baseline smoking (χ2 = 6.33), unmarried (χ2 = 12.0), hypertension (χ2 = 5.72), greater body mass index (d = 0.45), and physical fatigue (d = 0.25) were related to higher CRP levels (p values < .05). Cross-sectionally, CRP levels were negatively related to MoCA scores, beyond CVD (ΔR2 = 0.022, β = -0.170, p < .010) and psychological risk factors (ΔR2 = 0.016, β = 0.145, p < .027), and related to mild cognitive impairment criteria (odds ratio = 1.35, 95% confidence interval [CI] = 1.00-1.81, p = .046). Across 12 months, B-type natriuretic peptide high-risk patients with CRP levels ≥3 mg/L had lower MoCA scores (23.6; 95% CI = 22.4-24.8) than did patients with CRP levels <3 mg/L (25.4; 95% CI = 24.4-26.5; p = .024). CONCLUSIONS: Patients with stage B HF and heightened CRP levels had greater cognitive impairment at baseline and follow-up, independent of CVD and potentially psychological risk factors. Low-grade systemic inflammation may be one mechanism involved in cognitive dysfunction at early stages of HF.
No takes yet. Share an insight, caveat, or question.
Redwine et al. (2021) conducted an observational in Stage B heart failure (n=270). C-reactive protein (CRP) vs. Lower CRP levels was evaluated on Mild cognitive impairment (OR 1.35, 95% CI 1.00-1.81, p=.046). Higher C-reactive protein levels were associated with mild cognitive impairment (OR 1.35; 95% CI 1.00-1.81; P=0.046) in patients with stage B heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: